DexCom, Inc. (DXCM)
| Market Cap | 28.64B -13.9% |
| Revenue (ttm) | 4.82B +16.2% |
| Net Income | 930.40M +73.8% |
| EPS | 2.34 +75.5% |
| Shares Out | 385.87M |
| PE Ratio | 31.72 |
| Forward PE | 27.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,388,471 |
| Open | 75.70 |
| Previous Close | 75.37 |
| Day's Range | 73.53 - 75.70 |
| 52-Week Range | 54.11 - 89.98 |
| Beta | 1.44 |
| Analysts | Strong Buy |
| Price Target | 85.21 (+14.81%) |
| Earnings Date | Jul 29, 2026 |
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin;... [Read more]
Financial Performance
In 2025, DexCom's revenue was $4.66 billion, an increase of 15.60% compared to the previous year's $4.03 billion. Earnings were $836.30 million, an increase of 45.14%.
Financial StatementsAnalyst Summary
According to 27 analysts, the average rating for DXCM stock is "Strong Buy." The 12-month stock price target is $85.21, which is an increase of 14.81% from the latest price.
News
DexCom price target raised to $88 from $75 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on DexCom (DXCM) to $88 from $75 and keeps an Overweight rating on the shares. The firm is updating a…
FDA clears first over-the-counter glucose monitor for children
The U.S. Food and Drug Administration said on Friday it has expanded the use of Dexcom's Stelo Glucose Biosensor System to children with diabetes, making it the first over-the-counter continuous glu...
DexCom’s over-the-counter CGM for children cleared for marketing by FDA
The U.S. Food and Drug Administration cleared for marketing the first over-the-counter continuous glucose monitor for children, Dexcom (DXCM) Inc.’s Stelo Glucose Biosensor System, an integrated CGM i...
Pharmsource says it was unaware Dexcom sensors it bought were slated for destruction
Drug wholesaler Pharmsource LLC said it was unaware the Dexcom glucose sensors it bought from licensed distributors had been slated for destruction, after the device maker warned some units were sto...
DexCom price target raised to $95 from $75 at TD Cowen
TD Cowen analyst Joshua Jennings raised the firm’s price target on DexCom (DXCM) to $95 from $75 and keeps a Buy rating on the shares. The firm said the company…
DexCom price target raised to $85 from $75 at Mizuho
Mizuho raised the firm’s price target on DexCom (DXCM) to $85 from $75 and keeps an Outperform rating on the shares after attending the American Diabetes Association meeting. DexCom’s randomized…
DexCom price target raised to $91 from $81 at Raymond James
Raymond James raised the firm’s price target on DexCom (DXCM) to $91 from $81 and keeps a Strong Buy rating on the shares. While acknowledging the high expectations, the CONNECT…
DexCom announces results from CONNECT trial of Dexcom G7
DexCom (DXCM) announced results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in g...
Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study
Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not using insulin, compared with routine care, acc...
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically si...
DexCom price target raised to $90 from $85 at Stifel
Stifel analyst Jonathan Block raised the firm’s price target on DexCom (DXCM) to $90 from $85 and keeps a Buy rating on the shares. The firm’s survey of 35 doctors,…
DexCom to present new clinical findings, advancements at ADA’s Sessions
DexCom (DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and usherin...
Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for peop...
Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc., the global leader in glucose biosensing, today released its inaugural Customer Advisory Council Report, detailing candid feedback from users, caregivers, heal...
DexCom price target raised to $84 from $79 at Citi
Citi raised the firm’s price target on DexCom (DXCM) to $84 from $79 and keeps a Buy rating on the shares. The firm updated models in the medical technology space…
Signos grows foothold in weight-loss wave fueled by GLP-1s with its AI health data tracking
Health tech startup Signos announced a $20 million funding round and expanded its partnership with medical device giant Dexcom. Signos makes an AI-powered glucose monitoring system designed to help wi...
DexCom identifies theft of scrapped Dexcom G7 sensors
DexCom (DXCM) announced through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen ...
Dexcom warns patients as stolen glucose sensors hit the market
Medical device maker Dexcom said on Tuesday some of its glucose sensors slated for destruction were instead stolen and sold, prompting the company to warn users not to use products from two affected...
Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of ...
DexCom announces Dexcom Flex in Germany
DexCom (DXCM) announced Dexcom Flex, a new CGM system designed specifically for adults with Type 2 diabetes who are not using intensive insulin therapy. The new system will be available…
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany
SAN DIEGO & EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today announced Dexcom Flex, a new CGM system designed specifically for...
DexCom price target lowered to $80 from $100 at BofA
BofA analyst Travis Steed lowered the firm’s price target on DexCom (DXCM) to $80 from $100 and keeps a Buy rating on the shares following the company’s analyst day and…
DexCom price target lowered to $82 from $100 at Canaccord
Canaccord lowered the firm’s price target on DexCom (DXCM) to $82 from $100 and keeps a Buy rating on the shares. The firm atteended its Investor Day where management outlined…
DexCom price target lowered to $64 from $67 at Barclays
Barclays analyst Matt Miksic lowered the firm’s price target on DexCom (DXCM) to $64 from $67 and keeps an Underweight rating on the shares. The company’s investor day set the…
Why Is Dexcom Stock (DXCM) Soaring Today?
Dexcom ($DXCM) stock jumped about 8% on Friday, at the time of writing, as activist investor Elliott Investment Management took a stake in the maker of continuous glucose monitoring (CGM)…